Compare ARK Genomic Revolution ETF (ARKG) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Prospect Capital Corporation — how do they compare? ARK Genomic Revolution ETF trades at $41.2, while Prospect Capital Corporation trades at $2.26 (market cap $1.13B). The key difference: Prospect Capital Corporation pays a 22.17% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Prospect Capital Corporation nearer its low. Which is the better fit depends on your goals.
| ARKG | PSEC | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $43.57 | $3.47 |
52-Week Low | $23.09 | $2.15 |
Market Cap | — | $1.13B |
Dividend Yield | — | 22.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
PSEC trades at $2.26, up 2.26% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.38 and has beaten EPS estimates for three consecutive quarters. Recent news includes a new investment in ShipOffers and the sale of Valley Electric generating $328 million. Dividend payments continue at $0.04-$0.05 monthly, supporting income appeal despite negative revenue and net income in 2025.
Outlook remains cautious due to persistent negative profitability and revenue volatility, though deep discount to NAV and high yield may attract income investors. Key risks include declining NAV, portfolio quality concerns, and analyst skepticism. Upside depends on stabilization of investment income and successful execution of senior lending strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
